This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rodman Rambles: The Biotech Dreck

NEW YORK ( TheStreet) -- I sat through investor presentations by Cell Therapeutics (CTIC - Get Report), Rexahn Pharmaceuticals (RNN), Oculus Innovative Sciences (OCLS - Get Report) and Hemispherx Biopharma (HEB - Get Report) all before lunch Tuesday. Surely, torture like that is deserving of a workers' compensation claim.

The forum for this circus of biotech ineptitude was the Rodman & Renshaw Annual Global Investment Conference. Rodman makes a good living as the go-to banker for the bottom of biotech barrel (heck, someone has to do it), so the firm's investor confab presents a unique opportunity to gawk at companies which most of Wall Street has written off.

Cell Therapeutics' CEO Jim Bianco told assembled investors that he's not begging for his company's survival, a reference to the headline of my column Monday which discussed the company's looming bankruptcy unless shareholders approve a plan Thursday to increase authorized shares by 400 million to 1.2 billion.

Bianco spent no time at all during his 20-minute presentation discussing the company's financial woes. (No surprise there.) During a brief Q&A session, Bianco did say the company was working harder to get Italian shareholders who control about 40% of the company's shares to vote in Thursday's shareholder meeting.

If Cell Therapeutics cannot get a quorum, the company won't be able to add authorized shares, and therefore will not be able to sell stock to raise much-needed cash. If that happens, Bianco said the company may sell preferred shares, take on more debt or look to sell assets in order to raise money. Of course, those alternative transactions depend on finding a willing counterparty -- certainly not a sure bet.

Bianco also commented on the company's decision to appeal the FDA's rejection of its lymphoma drug pixantrone. "It's the American thing to do," he said.

The FDA's cancer drug division savaged pixantrone in its review in March, which was followed by a unanimous 9-0 vote against the drug by the FDA's outside advisory panel and then a formal rejection of the drug by the agency.

Calling Cell Therapeutics' appeal of this resoundingly negative decision a Hail Mary would be too optimistic. FDA should rule on the pixantrone appeal before the end of the year. The answer, once again, is very likely to be no.

Cell Therapeutics shares dropped two cents, closing Tuesday at 37 cents a share, despite Bianco's attempt to cheer investors with news of the pixantrone appeal.

Rexahn CEO Chang Ahn didn't show up at the Rodman conference. Instead, he sent President Rick Soni, whose halting performance didn't instill much confidence in the company's future.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
HEB $0.12 -0.87%
OCLS $1.18 -0.83%
RNN $0.47 1.80%
CTIC $1.24 2.90%
AAPL $118.94 0.96%


Chart of I:DJI
DOW 17,798.49 0.00 0.00%
S&P 500 2,088.22 -1.89 -0.09%
NASDAQ 5,124.94 -2.5850 -0.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs